SEC Form 4 · accession 0000899243-19-005458
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marla Persky
Director
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.00 | Feb 27, 2019 | A | 20,000 | A | — | Feb 27, 2029 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F125% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.